Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2023-01-31 Regulatory Filings
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - IIQ 4 pages 24.2KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have lapsed due to conditions not being met. It includes details about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There are no financial statements, management discussion, or detailed financial data. The document is an official announcement related to changes in the company's securities but does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is a regulatory announcement about securities cessation, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2023-01-31 English
Notification regarding unquoted securities - IIQ 7 pages 29.5KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities under an employee incentive scheme by INOVIQ LTD. It details the number and type of securities issued, dates, and mentions key management personnel receiving securities. The content focuses on the issuance of securities and compliance with listing rules, without containing financial statements or performance data. This fits the definition of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document is about the issuance of options and shares, not a full financial report or other types of filings.
2023-01-31 English
Appendix 4C & Quarterly Activities Report - December 2022 9 pages 486.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4C & QUARTERLY BUSINESS UPDATE Period Ended 31 December 2022' and includes detailed quarterly cash flow statements, operational updates, R&D progress, commercial updates, and financial data for the quarter ended 31 December 2022. It references the ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting for listed entities in Australia. The document contains substantive financial data including cash receipts, payments, and net cash used in operating activities, as well as narrative business updates. It is not merely an announcement of a report but the actual quarterly report itself. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2023
2023-01-30 English
Resignation of Director 2 pages 206.6KB
Board/Management Information Classification · 100% confidence The document is a short announcement (3500 characters) about the resignation of a Non-Executive Director from the company's board, effective immediately. It includes details about the director's contributions and a statement from the Chairman. There is no financial data, no mention of a report or financial results, and no regulatory filings or certifications. The content clearly relates to a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under the category 'Board/Management Information' (MANG). The document is not a report or a regulatory filing but a straightforward management change announcement.
2022-12-13 English
Final Director's Interest Notice 2 pages 220.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including ordinary securities and unlisted incentive plan options, as well as interests in contracts. The document is a formal notice about a director's personal share transactions and holdings. It does not contain financial statements, earnings data, or management discussion. The content aligns with reporting of insider share transactions by directors. Therefore, the document fits the category of Director's Dealing (DIRS). The document length is short and focused solely on director interests, confirming this classification with high confidence.
2022-12-13 English
Positive EXO-NET Results in Ovarian Cancer 3 pages 262.1KB
Capital/Financing Update Classification · 85% confidence The document is an ASX release announcing the completion and positive results of a feasibility study (OC97) related to the development of an EV-based ovarian cancer test using the EXO-NET technology. It contains detailed scientific and clinical study results, including accuracy metrics and next steps for validation studies. The document is a corporate announcement focused on research progress and product development milestones rather than financial results, regulatory filings, or management changes. It does not contain financial statements, earnings data, or regulatory certifications. It is not a report publication announcement since it provides substantive content rather than just announcing a report's availability. The content aligns best with a Capital/Financing Update (CAP) category as it relates to the company's progress in product development and potential commercialisation, which is typical for updates on company activities that may impact capital or financing decisions. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-12-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.